Revision 1

#5493Store at -20C

 

Cell Signaling Technology

Orders: 877-616-CELL (2355) [email protected]

Support: 877-678-TECH (8324)

Web: [email protected] cellsignal.com

3 Trask LaneDanversMassachusetts01923USA
For Research Use Only. Not for Use in Diagnostic Procedures.
MW (kDa):

8

UniProt ID:

#Q6UW88

Entrez-Gene Id:

255324

Background

Epigen was identified as an EGF family member by amino acid sequence homology (1). The sequence was obtained from mouse keratinocyte mRNA. Epigen is expressed in normal human mammary tissue and in some prostate and breast carcinomas (2). Epigen binding to known EGF receptors is with lower affinity when compared to EGF. However, Epigen appears to be superior in inducing cell proliferation (2). Epigen induces responses in MDA-MB-468 breast carcinoma cells. Epigen also has effects on prostate cells and vascular endothelial cells (2). Epigen binds to ErbB1/Her1 (2). Binding causes receptor homodimerization and heterodimerization with other Erb/Her receptors (2).

  1. Strachan, L. et al. (2001) J Biol Chem 276, 18265-71.
  2. Kochupurakkal, B.S. et al. (2005) J Biol Chem 280, 8503-12.

Endotoxin

Less than 0.01 ng endotoxin/1 μg hEpigen.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hEpigen. All lots are greater than 98% pure.

Source / Purification

Recombinant human Epigen (hEpigen) Ala24-Ala104 (Accession #Q6UW88-1) was produced in E. coli at Cell Signaling Technology.

Bioactivity

The bioactivity of recombinant hEpigen was determined in a MCF-10A cell proliferation assay. The ED50 of each lot is between 2-30 ng/ml.

Background

Epigen was identified as an EGF family member by amino acid sequence homology (1). The sequence was obtained from mouse keratinocyte mRNA. Epigen is expressed in normal human mammary tissue and in some prostate and breast carcinomas (2). Epigen binding to known EGF receptors is with lower affinity when compared to EGF. However, Epigen appears to be superior in inducing cell proliferation (2). Epigen induces responses in MDA-MB-468 breast carcinoma cells. Epigen also has effects on prostate cells and vascular endothelial cells (2). Epigen binds to ErbB1/Her1 (2). Binding causes receptor homodimerization and heterodimerization with other Erb/Her receptors (2).

Background References

    Cross-Reactivity Key

    H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected

    Trademarks and Patents

    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    Revision 1
    #5493

    Human Epigen

    Human Epigen: Image 1 Expand Image
    The proliferation of MCF-10A cells treated with increasing concentrations of hEpigen was assessed. After 24 hr treatment, cells were labeled with BrdU for 4 hr. BrdU incorporation was determined by ELISA and the OD450-OD690 was determined.
    Human Epigen: Image 2 Expand Image
    The purity of recombinant hEpigen was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hEpigen and staining overnight with Coomassie Blue.
    Human Epigen: Image 3 Expand Image
    Western blot analysis of extracts from MCF-10A cells untreated or treated with hEpigen for 10 minutes, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (upper) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (lower).